Table 3

Relative decreases in HAM-D scores for subgroups of patients with a major depressive episode after 6 weeks of treatment with WS® 5570 or placebo (full analysis set, last observation carried forward)

Subgroup based on baseline score
Mean % decrease ± SD, number of patients
p-value





WS® 5570 600 mg/day N = 119
WS® 5570 1200 mg/day N = 124
Placebo N = 81
WS® 5570 600 mg/day vs placebo
WS® 5570 1200 mg/day vs placebo

Baseline HAM-D total score cutoff 20 (split at 25th percentile)
<20
54.2 ± 26.3, 25
56.0 ± 29.9, 31
32.7 ± 40.5, 14
0.09
0.07

≥ 20
51.1 ± 28.3, 94
46.4 ± 32.5, 93
24.4 ± 33.6, 67
<0.001
<0.001
Baseline HAM-D total score cutoff 23 (split at median)
<23
55.5 ± 28.1, 56
53.1 ± 29.7, 64
26.8 ± 38.8, 37
<0.001
<0.001

≥ 23
48.4 ± 27.4, 63
44.2 ± 33.9, 60
25.1 ± 31.4, 44
<0.001
<0.01
Baseline HAM-D total score cutoff 25 (split at 75th percentile)
<25
53.6 ± 27.3, 83
52.8 ± 30.2, 85
28.6 ± 37.7, 49
<0.001
<0.001

≥ 25
47.4 ± 28.9, 36
40.2 ± 34.5, 39
21.7 ± 29.8, 32
<0.001
0.02
Baseline CGI item 1, severity of illness
<5*
51.2 ± 28.7, 67
49.9 ± 31.5, 62
28.0 ± 36.1, 46
<0.001
<0.01

≥ 5§
52.4 ± 26.9, 52
47.7 ± 32.7, 62
23.1 ± 33.3, 35
<0.001
<0.001

* "Moderately ill or less severe"

§ "Markedly ill or more severe"

Kasper et al. BMC Medicine 2006 4:14   doi:10.1186/1741-7015-4-14